Only a small fraction of people living in low-income countries will have received at least one dose of the SARS-CoV-2 vaccine by the end of 2021. By contrast, booster shots of the mRNA vaccines are being administered in vaccine-rich countries despite an absence of consensus regarding the need for an additional dose.1 Adults working in high-risk settings, including health-care workers, are currently eligible for a COVID-19 vaccine booster in some countries, including the USA, the UK, Germany, and Italy. However, the evidence supporting this policy is controversial.
Early studies documenting waning immunity to SARS-CoV-2 in mRNA vaccine recipients used antibody titres and infection rates (positive PCR test) as outcome measures;1, 2 however, no evidence was found for an appreciable waning of protection against hospital admission and death 6 months after the second dose of Pfizer-BioNTech's BNT162b2 mRNA COVID-19 vaccine.2 In a recent observational study from Israel, the authors could not show the effectiveness of a third dose of BNT162b2 for preventing severe outcomes in younger age groups (16–39 years).3 In the subgroup analysis, triple-vaccinated individuals older than 40 years had decreased rates of admission to hospital, severe disease, and COVID-19-related death compared with those who had received only two doses. In this study, individuals aged 40–69 years were stratified into the same group, which might have skewed the results, given that a third BNT162b2 vaccine dose was shown to be protective in individuals aged 60 years or older.4
The second crucial element relates to which categories of health-care workers belong to high-risk groups. For example, the risk of testing positive for SARS-CoV-2 was greater among front-line workers (defined as those with direct patient contact) than among the general community, and the risk of hospital admission among front-door workers (defined as paramedics or workers in other acute-receiving specialities) and personnel exposed to aerosol-generating procedures was higher than among other front-line health-care workers.5 However, it has also been reported that occupational risk for unvaccinated health-care providers who routinely undertake aerosol-generating procedures6 was relatively low during the first wave of the COVID-19 pandemic, as was the risk for non-patient-facing health-care workers and their households.5
Although expert opinion predicts that everyone will need a booster dose at some point, it would be reasonable if boosters were given only to targeted populations in whom the evidence shows they are probably needed. On a global scale, this would avoid millions of unnecessary adverse effects and, most importantly, would make those vaccines available to countries where they are most needed. After all, a worldwide epidemic—a pandemic—requires a global strategy.
I declare no competing interests.
References
- 1.Burki T. Booster shots for COVID-19—the debate continues. Lancet Infect Dis. 2021;21:1359–1360. doi: 10.1016/S1473-3099(21)00574-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021 doi: 10.1056/NEJMoa2114114. published online Oct 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 doi: 10.1016/S0140-6736(21)02249-2. published online Oct 29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385:1393–1400. doi: 10.1056/NEJMoa2114255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Shah ASV, Wood R, Gribben C, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ. 2020;371 doi: 10.1136/bmj.m3582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Araujo MWB, Estrich CG, Mikkelsen M, et al. COVID-2019 among dentists in the United States: a 6-month longitudinal report of accumulative prevalence and incidence. J Am Dent Assoc. 2021;152:425–433. doi: 10.1016/j.adaj.2021.03.021. [DOI] [PMC free article] [PubMed] [Google Scholar]